StateWatch: Bill Review October 2018
2 MIN READ
Keep current with new legislation and its potential effect on your organization. This regulatory update is for informational purposes only, and provides some key highlights on state initiatives that may impact the bill review services Genex provides.
2019 CMS Medicare Payments: Proposed Changes and What They Mean for P&C Insurers
Several states in auto and workers’ compensation claims administration have adopted the Centers of Medicare and Medicaid Services’ (CMS) fee schedules and/or rules for payment of claims. The methodologies employed by CMS in provider billing and payment are typically either mandated by statute or become standards for appropriate billing and payment of claims. When Medicare adds new codes or proposes changes to fee schedules, Mitchell prepares for these changes by reviewing the proposed changes and how they could affect the Property and Casualty industry.
Before You Choose a PBM, do the Math
11 MIN READ
Cost is black & white Price alone isn’t. Your PBM must also control utilization or you’ll be seeing red.
Five Initial Evaluation Issues That May Delay Return to Work
When there’s a return to work delay, practitioners often look for problems that occurred during the course of treatment. However, as Mariellen Blue, Genex’s National Director of Case Management Services, tells us in today’s Inside Workers’ Comp, you may have to go back a little further in the recovery plan to find the answer. Check out the five reasons why the initial evaluation may be the culprit.
A New Era of Performance Management
As McKinsey and Company stated in their 2017 study on performance management, “What gets measured, gets done.”1 Performance management is a critical aspect of success in any field of business, and this is especially true in the world of auto physical damage claims. Success comes in many forms in the claims industry, from managing costs to producing proper and safe repairs.
StateWatch: Fall 2018
11 MIN READ
Keep current with new legislation and its potential effect on your organization. This regulatory update is for informational purposes only, and provides some key highlights on state initiatives that may impact the services Genex provides.
StateWatch: Fall 2018
11 MIN READ
The FDA has approved a non-opioid, percutaneous electrical nerve field stimulator device as an aid to reduce opioid withdrawal symptoms during detoxification.